Northern Trust
EGRX

Northern Trust’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Northern Trust’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-31,955
Closed -$119K – 4539
2024
Q3 		$119K Sell
31,955
-62,107
-66% -$296K ﹤0.01% 4011
2024
Q2 		$527K Sell
94,062
-5,440
-5% -$23.7K ﹤0.01% 3492
2024
Q1 		$521K Sell
99,502
-6,471
-6% -$35.5K ﹤0.01% 3549
2023
Q4 		$554K Buy
105,973
+8,726
+9% +$86.1K ﹤0.01% 3505
2023
Q3 		$1.53M Sell
97,247
-9,986
-9% -$179K ﹤0.01% 3079
2023
Q2 		$2.08M Sell
107,233
-13,520
-11% -$321K ﹤0.01% 2981
2023
Q1 		$3.43M Buy
120,753
+2,429
+2% +$72.1K ﹤0.01% 2679
2022
Q4 		$3.46M Buy
118,324
+2,325
+2% +$73.9K ﹤0.01% 2695
2022
Q3 		$3.06M Sell
115,999
-47,102
-29% -$1.73M ﹤0.01% 2775
2022
Q2 		$7.25M Buy
163,101
+22,794
+16% +$1.05M ﹤0.01% 2268
2022
Q1 		$6.94M Sell
140,307
-3,724
-3% -$179K ﹤0.01% 2374
2021
Q4 		$7.33M Sell
144,031
-4,891
-3% -$253K ﹤0.01% 2455
2021
Q3 		$8.31M Sell
148,922
-4,242
-3% -$209K ﹤0.01% 2413
2021
Q2 		$6.55M Buy
153,164
+19,001
+14% +$784K ﹤0.01% 2665
2021
Q1 		$5.6M Sell
134,163
-3,194
-2% -$148K ﹤0.01% 2677
2020
Q4 		$6.4M Sell
137,357
-8,813
-6% -$412K ﹤0.01% 2534
2020
Q3 		$6.21M Sell
146,170
-5,661
-4% -$248K ﹤0.01% 2398
2020
Q2 		$7.29M Buy
151,831
+16,686
+12% +$833K ﹤0.01% 2291
2020
Q1 		$6.22M Buy
135,145
+1,640
+1% +$82.3K ﹤0.01% 2177
2019
Q4 		$8.02M Sell
133,505
-3,711
-3% -$221K ﹤0.01% 2323
2019
Q3 		$7.76M Sell
137,216
-8,381
-6% -$471K ﹤0.01% 2297
2019
Q2 		$8.11M Buy
145,597
+529
+0.4% +$27.6K ﹤0.01% 2280
2019
Q1 		$7.32M Sell
145,068
-737
-0.5% -$32.8K ﹤0.01% 2336
2018
Q4 		$5.88M Sell
145,805
-35,975
-20% -$1.85M ﹤0.01% 2405
2018
Q3 		$12.6M Buy
181,780
+17,209
+10% +$1.3M ﹤0.01% 2124
2018
Q2 		$12.5M Buy
164,571
+30,773
+23% +$1.94M ﹤0.01% 2128
2018
Q1 		$7.05M Buy
133,798
+5,495
+4% +$320K ﹤0.01% 2388
2017
Q4 		$6.85M Sell
128,303
-4,382
-3% -$244K ﹤0.01% 2419
2017
Q3 		$7.91M Buy
132,685
+18,039
+16% +$1.09M ﹤0.01% 2346
2017
Q2 		$9.05M Sell
114,646
-2,211
-2% -$181K ﹤0.01% 2242
2017
Q1 		$9.69M Buy
116,857
+6,638
+6% +$494K ﹤0.01% 2143
2016
Q4 		$8.74M Buy
110,219
+2,970
+3% +$216K ﹤0.01% 2203
2016
Q3 		$7.51M Sell
107,249
-633
-0.6% -$35.1K ﹤0.01% 2255
2016
Q2 		$4.18M Buy
107,882
+7,516
+7% +$313K ﹤0.01% 2582
2016
Q1 		$4.07M Buy
100,366
+1,666
+2% +$106K ﹤0.01% 2531
2015
Q4 		$8.75M Buy
98,700
+2,771
+3% +$219K ﹤0.01% 2102
2015
Q3 		$7.1M Buy
95,929
+69,982
+270% +$5.82M ﹤0.01% 2229
2015
Q2 		$2.1M Buy
25,947
+15,820
+156% +$1.03M ﹤0.01% 3036
2015
Q1 		$424K Buy
+10,127
New +$287K ﹤0.01% 3654
2014
Q3 		– Sell
-31,024
Closed -$444K – 4364
2014
Q2 		$444K Buy
+31,024
New +$354K ﹤0.01% 3627

Other funds holding EGRX

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
AIC
Archer Investment Corporation Carmel, Indiana $469M AUM 19.1% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Northern Trust's EGRX Position: Q4 2024 in Review

Northern Trust sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2024, closing a stake of 31,955 shares — an estimated $119K sold.

Northern Trust first reported a position in EGRX in Q2 2014 and held it in 40 quarters. The position peaked at $12.6M in Q3 2018. 9 funds tracked by Wall St. Rank hold EGRX as of Q4 2024.

  • Northern Trust reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2024 after selling out during the quarter.
  • Northern Trust sold 31,955 Eagle Pharmaceuticals, Inc. shares in Q4 2024, an estimated $119K.
  • Northern Trust first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2014 and held it in 40 quarters.
  • Northern Trust's Eagle Pharmaceuticals, Inc. position peaked at $12.6M in Q3 2018.
  • 9 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2024.

Based on Northern Trust's 13F filing for Q4 2024, filed 14 Feb 2025.